Dippel, E J; Kereiakes, D J; Tramuta, D A; Broderick, T M; Shimshak, T M; Roth, E M; Hattemer, C R; Runyon, J P; Whang, D D; Schneider, J F; Abbottsmith, C W 2001. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 52 3, 279-86
Kereiakes, D J; Obenchain, R L; Barber, B L; Smith, A; McDonald, M; Broderick, T M; Runyon, J P; Shimshak, T M; Schneider, J F; Hattemer, C R; Roth, E M; Whang, D D; Cocks, D; Abbottsmith, C W 2000. Abciximab provides cost-effective survival advantage in high-volume interventional practice. American heart journal, 140 4, 603-10
Kereiakes, D J; Broderick, T M; Roth, E M; Whang, D; Shimshak, T; Runyon, J P; Hattemer, C; Schneider, J; Lacock, P; Mueller, M; Abbottsmith, C W 1999. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. The American journal of cardiology, 84 4, 391-5
Ritchie, M E; Hattemer, C; Lenihan, D 1998. Ergonovine-testing-directed therapy and long-term outcome of sudden-death survivors with no apparent heart disease. Cardiology, 89 1, 76-8
Gibler, W B; Runyon, J P; Levy, R C; Sayre, M R; Kacich, R; Hattemer, C R; Hamilton, C; Gerlach, J W; Walsh, R A 1995. A rapid diagnostic and treatment center for patients with chest pain in the emergency department. Annals of emergency medicine, 25 1, 1-8
Yingling, K W; Hattemer, C; Rouan, G W; Luke, R G 1991. Internal medicine residents' monitoring of their colleagues' moonlighting activities at the University of Cincinnati. Academic medicine : journal of the Association of American Medical Colleges, 66 11, 705-6
